These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28369750)

  • 1. Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis.
    Ovejero-Benito MC; Cabaleiro T; Sanz-García A; Llamas-Velasco M; Saiz-Rodríguez M; Prieto-Pérez R; Talegón M; Román M; Ochoa D; Reolid A; Daudén E; Abad-Santos F
    Br J Dermatol; 2018 Mar; 178(3):798-800. PubMed ID: 28369750
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR; Duarte B; Ferreira A; Cabete J
    Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
    [No Abstract]   [Full Text] [Related]  

  • 4. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked decrease in serum squamous cell carcinoma antigen level after antitumor necrosis factor alpha therapy in six cases of severe psoriasis.
    Iriki H; Tanese K; Furuichi Y; Takeshita K; Saito M
    Int J Dermatol; 2016 Jun; 55(6):e364-6. PubMed ID: 26696364
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalised pustular psoriasis and neutrophilic cholangitis: An infrequently reported association with excellent response to tumour necrosis factor inhibitors.
    Rodríguez-Lomba E; Baniandrés O; Cano N; Suárez-Fernández R
    Australas J Dermatol; 2017 Feb; 58(1):70-71. PubMed ID: 28195322
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
    Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
    Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival of biologic treatments in psoriasis: a systematic review.
    No DJ; Inkeles MS; Amin M; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):460-466. PubMed ID: 29076754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of TNF-α antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports.
    Vural S; Arakawa A; Arakawa Y; Prinz JC
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):e418-e419. PubMed ID: 29705991
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of human cytomegalovirus infection and T-cell response in patients with psoriasis before and during antitumour necrosis factor-α therapy.
    Fornara L; Fornara C; Cananzi R; Lilleri D; Furione M; Brazzelli V
    Br J Dermatol; 2017 Dec; 177(6):e323-e324. PubMed ID: 28494092
    [No Abstract]   [Full Text] [Related]  

  • 17. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy.
    Pirmit S; Onsun N; Su O; Ozkaya DB
    G Ital Dermatol Venereol; 2017 Apr; 152(2):126-131. PubMed ID: 28166613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.
    Rousset L; de Masson A; Begon E; Villani A; Battistella M; Rybojad M; Jachiet M; Bagot M; Bouaziz JD; Lepelletier C
    J Am Acad Dermatol; 2019 Apr; 80(4):1141-1143. PubMed ID: 30342166
    [No Abstract]   [Full Text] [Related]  

  • 19. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
    J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.